Resveratrol reduces cardiac NLRP3‐inflammasome activation and systemic inflammation to lessen doxorubicin‐induced cardiotoxicity in juvenile mice

Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure

(2020) Nikole J. Byrne et al.   Circulation-Heart Failure

Resveratrol protects against CIH-induced myocardial injury by targeting Nrf2 and blocking NLRP3 inflammasome activation

(2020) Zhi-Min Sun et al.   LIFE SCIENCES

Metabolic Plasticity in Chemotherapy Resistance

(2020) Maria Andrea Desbats et al.   Frontiers in Oncology

Dihydromyricetin alleviates doxorubicin-induced cardiotoxicity by inhibiting NLRP3 inflammasome through activation of SIRT1

(2020) Zhenzhu Sun et al.   BIOCHEMICAL PHARMACOLOGY

The beneficial effects of reducing NLRP3 inflammasome activation in the cardiotoxicity and the anti-cancer effects of doxorubicin

(2020) Zaid H. Maayah et al.   ARCHIVES OF TOXICOLOGY

New Noonan syndrome model mice with RIT1 mutation exhibit cardiac hypertrophy and susceptibility to β-adrenergic stimulation-induced cardiac fibrosis

(2019) Shingo Takahara et al.   EBioMedicine

Trimethylamine N-Oxide Exacerbates Cardiac Fibrosis via Activating the NLRP3 Inflammasome

(2019) Xueling Li et al.   Frontiers in Physiology

NLRP3 inflammasome in fibroblasts links tissue damage with inflammation in breast cancer progression and metastasis

(2019) Nour Ershaid et al.   Nature Communications

Protective Effect of Resveratrol Improves Systemic Inflammation Responses in LPS-Injected Lambs

(2019) Yanping Liang et al.   Animals

Co-administration of resveratrol with doxorubicin in young mice attenuates detrimental late-occurring cardiovascular changes

(2018) Nobutoshi Matsumura et al.   CARDIOVASCULAR RESEARCH

2-Methoxyestradiol protects against pressure overload-induced left ventricular hypertrophy

(2018) Zaid H. Maayah et al.   Scientific Reports

Resveratrol ameliorates LPS-induced acute lung injury via NLRP3 inflammasome modulation

(2016) Lei Jiang et al.   BIOMEDICINE & PHARMACOTHERAPY

Doxorubicin-Induced Systemic Inflammation Is Driven by Upregulation of Toll-Like Receptor TLR4 and Endotoxin Leakage

(2016) Lintao Wang et al.   CANCER RESEARCH

Resveratrol alleviates sepsis-induced myocardial injury in rats by suppressing neutrophil accumulation, the induction of TNF-α and myocardial apoptosis via activation of Sirt1

(2016) Rui An et al.   Molecular Medicine Reports

CYP1B1 inhibition attenuates doxorubicin-induced cardiotoxicity through a mid-chain HETEs-dependent mechanism

(2016) Zaid H. Maayah et al.   PHARMACOLOGICAL RESEARCH

Pharmacologic Inhibition of the NLRP3 Inflammasome Preserves Cardiac Function After Ischemic and Nonischemic Injury in the Mouse

(2015) Carlo Marchetti et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Left Ventricular Dysfunction and CXCR3 Ligands in Hypertension: From Animal Experiments to a Population-Based Pilot Study

(2015) Raffaele Altara et al.   PLoS One

Managing Chemotherapy-Related Cardiotoxicity in Survivors of Childhood Cancers

(2014) Steven E. Lipshultz et al.   PEDIATRIC DRUGS

Both aerobic exercise and resveratrol supplementation attenuate doxorubicin-induced cardiac injury in mice

(2013) Vernon W. Dolinsky et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Resveratrol prevents hypertension and cardiac hypertrophy in hypertensive rats and mice

(2013) Vernon W. Dolinsky et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Fibrosis and heart failure

(2012) Ana Maria Segura et al.   HEART FAILURE REVIEWS

Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases

(2012) Charles A. Dinarello et al.   NATURE REVIEWS DRUG DISCOVERY

Interleukin-1 signaling mediates acute doxorubicin-induced cardiotoxicity

(2011) Jinzhou Zhu et al.   BIOMEDICINE & PHARMACOTHERAPY

Doxorubicin and daunorubicin induce processing and release of interleukin-1β through activation of the NLRP3 inflammasome

(2011) Kristin A. D. Sauter et al.   CANCER BIOLOGY & THERAPY

Continued Postnatal Administration of Resveratrol Prevents Diet-Induced Metabolic Syndrome in Rat Offspring Born Growth Restricted

(2011) V. W. Dolinsky et al.   DIABETES

Recombinant human interleukin-1 receptor antagonist protects mice against acute doxorubicin-induced cardiotoxicity

(2010) Jinzhou Zhu et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Calorie Restriction Prevents Hypertension and Cardiac Hypertrophy in the Spontaneously Hypertensive Rat

(2010) Vernon W. Dolinsky et al.   HYPERTENSION

Toll-like receptor-4 deficiency attenuates doxorubicin-induced cardiomyopathy in mice

(2008) Alexander Riad et al.   EUROPEAN JOURNAL OF HEART FAILURE

Exercise Preconditioning Protects against Doxorubicin-Induced Cardiac Dysfunction

(2008) DAVID S. HYDOCK et al.   MEDICINE AND SCIENCE IN SPORTS AND EXERCISE